Article
Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.
Current medicinal chemistry - 1 Jan 2010
Lassalle Sandra, Hofman Véronique, Ilie Marius, Butori Catherine, Bozec Alexandre, Santini José, Vielh Philippe, Hofman Paul
Abstract excerpt
A BRAF somatic mutation at residue 600 of the BRAF protein (BRAFV600E) is highly prevalent in papillary thyroid carcinomas (PTC). This mutation occurs in approximately 44% (from 29% to 83%) of PTC depending on the different studies. BRAFV600E is almost always found in PTC with a papillary or a mixed follicular/papillary architecture, being rarer in other subtypes of PTC. The discovery of the BRAFV600E mutation in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.